Skip to main content
OpenTrials

Clinical trial condition

Pulmonary Disease, Chronic Obstructive

Explore clinical trials studying Pulmonary Disease, Chronic Obstructive. Study availability and eligibility vary by location and protocol.

4,000 public trials 389 recruiting studies
Refine in advanced search Browse all conditions

Pulmonary Disease, Chronic Obstructive trial results

Completed

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

NCT00821093

Conditions
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD), Disease Attributes, +10 more
Locations
  • Novartis Investigator Site Anniston, Alabama, United States
  • Novartis Investigator Site Fairhope, Alabama, United States
  • Novartis Investigator Site Jasper, Alabama, United States
  • Novartis Investigator Site Mobile, Alabama, United States
View all 144 locations
View Trial Details
Completed

A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00622635

Conditions
Chronic Disease, Chronic Obstructive Pulmonary Disease, Disease Attributes, +6 more
Locations
  • Novartis Investigator Site Normal, Illinois, United States
  • Novartis Investigator Site Shawnee Mission, Kansas, United States
  • Novartis Investigator Site Lafayette, Louisiana, United States
  • Novartis Investigator Site Charlotte, North Carolina, United States
View all 14 locations
View Trial Details
Completed

Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00403845

Conditions
Chronic Disease, Chronic Obstructive Pulmonary Disease, Disease Attributes, +6 more
Locations
  • Novartis Investigative site Kasukabe, Japan
  • Novartis Investigator Site Kishiwada, Japan
  • Novartis Investigative Site Kurume, Japan
  • Novartis Investigative Site Obihiro, Japan
View Trial Details
Completed

Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)

NCT00792805

Conditions
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD), Disease Attributes, +6 more
Locations
  • Novartis Investigative Site Adelaide, Australia
  • Novartis Investigative Site Clayton, Australia
  • Novartis Investigative Site Daw Park, Australia
  • Novartis Investigative Site Beijing, China
View all 15 locations
View Trial Details
Completed

The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT00620022

Conditions
Chronic Disease, Chronic Obstructive Pulmonary Disease, Disease Attributes, +6 more
Locations
  • Novartis Investigator Site Torrance, California, United States
  • Novartis Investigator Site Lebanon, New Hampshire, United States
  • Novartis Investigator Site Brussels, Belgium
  • Novartis Investigator Site Gembloux, Belgium
View all 20 locations
View Trial Details
Completed

Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00794157

Conditions
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD), Disease Attributes, +6 more
Locations
  • Novartis Investigator Site Hong Kong
  • Novartis Investigator Site New Territories, Hong Kong
  • Novartis Investigative Site Ahmedabad, India
  • Novartis Investigator Site Bangalore, India
View all 60 locations
View Trial Details
Completed

Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00615030

Conditions
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD), Disease Attributes, +6 more
Locations
  • Novartis Investigative Site Beuvry, France
  • Novartis Investigative Site Nantes, France
  • Novartis Investigative Site Berlin, Germany
  • Novartis Investigative Site Hamburg, Germany
View Trial Details
Completed

A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control

NCT00615459

Conditions
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD), Disease Attributes, +6 more
Locations
  • Novartis Investigative site Camperdown, Australia
  • Novartis Investigator Site Gauting, Germany
  • Novartis Investigator Site Großhansdorf, Germany
  • Novartis Investigator Site Mainz, Germany
View all 20 locations
View Trial Details

Related conditions